Table 1.
Selected characteristics at initial visit for participants in the Women’s Circle of Health Follow-Up Study (as of March 2018)
| Group 1: Full cohort (2005–2018) n=1719 |
Group 2: Invited and consented to the follow-up study (2013–2018) n=956 |
Group 3: Completed F/U 1 visit (2013–2018) n=530 |
Group 4: Donated blood during F/U 1 visit (2013–2018) n=400 |
|
|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | |
| Age at diagnosis (years) | ||||
| 20–40 | 175 (10.2) | 85 (8.9) | 51 (9.6) | 39 (9.8) |
| 41–60 | 1011 (58.8) | 542 (56.7) | 304 (57.4) | 230 (57.5) |
| 60–75 | 533 (31.0) | 329 (34.4) | 175 (33.0) | 131 (32.8) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Education | ||||
| ≤High school graduate | 668 (38.9) | 336 (35.2) | 192 (36.2) | 141 (35.3) |
| ≥Some college | 1049 (61.0) | 618 (64.6) | 338 (63.8) | 259 (64.8) |
| Missing | 2 (0.1) | 2 (0.2) | 0 (0.0) | 0 (0.0) |
| Insurance status (before diagnosis) | ||||
| Medicaid | 218 (12.7) | 129 (13.5) | 73 (13.8) | 53 (13.3) |
| Medicare | 267 (15.5) | 173 (18.1) | 95 (17.9) | 77 (19.3) |
| Private | 943 (54.9) | 499 (52.2) | 275 (51.9) | 201 (50.3) |
| Other | 93 (5.4) | 50 (5.2) | 28 (5.3) | 25 (6.3) |
| Uninsured | 188 (10.9) | 97 (10.2) | 56 (10.6) | 42 (10.5) |
| Missing | 10 (0.6) | 8 (0.8) | 3 (0.6) | 2 (0.5) |
| Family history of breast cancer (first-degree relative) | ||||
| No | 1414 (82.3) | 784 (82.0) | 434 (81.9) | 330 (82.5) |
| Yes | 305 (17.7) | 172 (18.0) | 96 (18.1) | 70 (17.5) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Smoking status (before diagnosis) | ||||
| Never | 1009 (58.7) | 566 (59.2) | 307 (57.9) | 232 (58.0) |
| Former | 421 (24.5) | 231 (24.2) | 130 (24.5) | 100 (25.0) |
| Current | 288 (16.8) | 158 (16.5) | 93 (17.6) | 68 (17.0) |
| Missing | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) |
| BMI (kg/m2 - measured during home visit at initial interview) | ||||
| Underweight (<18.5) | 8 (0.5) | 3 (0.3) | 3 (0.6) | 2 (0.5) |
| Normal (18.5–24.9) | 269 (15.7) | 141 (14.8) | 80 (15.1) | 61 (15.3) |
| Overweight (25.0–29.9) | 473 (27.5) | 267 (27.9) | 149 (28.1) | 123 (30.8) |
| Obese I (30.0–34.9) | 434 (25.3) | 246 (25.7) | 132 (24.9) | 97 (24.3) |
| Obese II (35.0–39.9) | 278 (16.2) | 163 (17.1) | 90 (17.0) | 64 (16.0) |
| Obese III (≥40.0) | 217 (12.6) | 110 (11.5) | 66 (12.5) | 45 (11.3) |
| Missing | 40 (2.3) | 26 (2.7) | 10 (1.9) | 8 (2.0) |
| Comorbidities before diagnosis (self-report) | ||||
| Hypertension | 740 (43.1) | 557 (58.3) | 310 (58.5) | 231 (57.8) |
| Diabetes | 280 (16.3) | 212 (22.2) | 118 (22.3) | 86 (21.5) |
| Heart disease or angina | 84 (4.9) | 71 (7.4) | 39 (7.4) | 27 (6.8) |
| Osteopenia or osteoporosis | 45 (2.6) | 45 (4.7) | 23 (4.3) | 17 (4.3) |
| Arthritis | 267 (15.5) | 252 (26.4) | 111 (20.9) | 76 (19.0) |
| Asthma | 147 (8.6) | 136 (14.2) | 68 (12.8) | 46 (11.5) |
| Sleep apnea | 83 (4.8) | 80 (8.4) | 35 (6.6) | 26 (6.5) |
| TUMOR CHARACTERISTICS | ||||
| Behavior | ||||
| DCIS | 334 (19.4) | 199 (20.8) | 113 (21.3) | 95 (23.8) |
| Invasive | 1385 (80.6) | 757 (79.2) | 417 (78.7) | 305 (76.3) |
| Unknown/missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Stage | ||||
| In situ | 285 (16.6) | 150 (15.7) | 107 (20.2) | 91 (22.8) |
| Localized only | 674 (39.2) | 315 (33.0) | 234 (44.2) | 182 (45.5) |
| Regional | 449 (26.1) | 221 (23.1) | 146 (27.5) | 99 (24.9) |
| Distant site(s)/node(s) involved | 64 (3.7) | 35 (3.7) | 17 (3.2) | 11 (2.8) |
| Unknown/missing | 247 (14.4) | 235 (24.5) | 26 (4.9) | 17 (4.3) |
| Grade | ||||
| I-Well differentiated | 168 (9.8) | 110 (11.5) | 70 (13.2) | 56 (14.0) |
| II-Moderately differentiated | 617 (35.9) | 356 (37.2) | 181 (34.2) | 132 (33.0) |
| III-Poorly differentiated | 722 (42.0) | 397 (41.5) | 227 (42.8) | 170 (42.5) |
| IV-Undifferentiated/anaplastic | 7 (0.4) | 1 (0.1) | 0 (0.0) | 0 (0.0) |
| Unknown/missing | 205 (11.9) | 92 (9.6) | 52 (9.8) | 42 (10.5) |
| ER | ||||
| Positive | 1224 (71.2) | 690 (72.2) | 382 (72.1) | 292 (73.0) |
| Negative | 474 (27.6) | 256 (26.8) | 145 (27.4) | 106 (26.5) |
| Unknown/missing | 21 (1.2) | 10 (1.1) | 3 (0.6) | 2 (0.5) |
| PR | ||||
| Positive | 947 (55.1) | 538 (56.3) | 295 (55.7) | 228 (57.0) |
| Negative | 746 (43.4) | 406 (42.5) | 230 (43.4) | 169 (42.3) |
| Unknown/missing | 26 (1.5) | 12 (1.3) | 5 (0.9) | 3 (0.8) |
| HER2 | ||||
| Positive | 290 (16.9) | 160 (16.7) | 88 (16.6) | 61 (15.3) |
| Negative | 1146 (66.7) | 645 (67.5) | 365 (68.9) | 275 (68.8) |
| Unknown/missing | 283 (16.5) | 151 (15.8) | 77 (14.5) | 64 (16.0) |
| Triple negative (ER-/PR-/HER2-) | ||||
| No | 1127 (65.6) | 636 (66.5) | 354 (66.8) | 262 (65.5) |
| Yes | 307 (17.9) | 167 (17.5) | 97 (18.3) | 73 (18.3) |
| Unknown/missing | 285 (16.6) | 153 (16.0) | 79 (14.9) | 65 (16.3) |
| TREATMENT INFORMATION (Self-report) | ||||
| Type of surgery | ||||
| Lumpectomy | 951 (55.3) | 510 (53.4) | 329 (62.1) | 247 (61.8) |
| Mastectomy | 604 (35.1) | 275 (28.8) | 175 (33.0) | 136 (34.0) |
| Missing | 145 (8.4) | 132 (13.8) | 9 (1.7) | 7 (1.8) |
| Chemotherapy | ||||
| Yes | 851 (49.5) | 429 (44.9) | 272 (51.3) | 202 (50.5) |
| No | 723 (42.0) | 395 (41.3) | 249 (47.0) | 191 (47.8) |
| Missing | 145 (8.4) | 132 (13.8) | 9 (1.7) | 7 (1.8) |
| Radiation therapy | ||||
| Yes | 879 (51.1) | 455 (47.6) | 284 (53.6) | 223 (55.8) |
| No | 694 (40.4) | 368 (38.5) | 237 (44.7) | 170 (42.5) |
| Missing | 146 (8.5) | 133 (13.9) | 9 (1.7) | 7 (1.8) |
| Endocrine therapy | ||||
| Yes | 739 (43.0) | 397 (41.5) | 267 (50.4) | 210 (52.5) |
| No | 830 (48.3) | 423 (44.3) | 252 (47.6) | 182 (45.5) |
| Missing | 150 (8.7) | 136 (14.2) | 11 (2.1) | 8 (2.1) |
| FIRST COURSE TREATMENT (Cancer Registry data) | ||||
| Type of surgery | ||||
| No surgery | 130 (7.6) | 74 (7.7) | 36 (6.8) | 27 (6.8) |
| Lumpectomy | 978 (56.9) | 572 (59.8) | 316 (59.6) | 238 (59.5) |
| Subcutaneous or total mastectomy | 361 (21.0) | 200 (20.9) | 121 (22.8) | 92 (23.0) |
| Radical mastectomy | 242 (14.1) | 105 (11.0) | 56 (10.6) | 43 (10.8) |
| Mastectomy, NOS | 1 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) |
| Surgery, NOS | 1 (0.1) | 4 (0.4) | 0 (0.0) | 0 (0.0) |
| Unknown/missing | 6 (0.4) | 74 (7.7) | 1 (0.2) | 0 (0.0) |
| Chemotherapy | ||||
| Yes, received | 793 (46.1) | 442 (46.2) | 246 (46.4) | 174 (43.5) |
| Not received | 776 (45.1) | 433 (45.3) | 243 (45.9) | 193 (48.3) |
| Recommended, not received | 59 (3.4) | 41 (4.3) | 22 (4.2) | 19 (4.8) |
| Recommended, unknown if received | 41 (2.4) | 20 (2.1) | 5 (0.9) | 4 (1.0) |
| Unknown/missing | 50 (2.9) | 20 (2.1) | 14 (2.6) | 10 (2.5) |
| Radiation therapy | ||||
| Yes | 777 (45.2) | 460 (48.1) | 255 (48.1) | 194 (48.5) |
| No | 819 (47.6) | 408 (42.7) | 235 (44.3) | 179 (44.8) |
| Recommended, but unknown if received | 78 (4.5) | 63 (6.6) | 22 (4.2) | 14 (3.5) |
| Unknown/missing | 45 (2.6) | 25 (2.6) | 18 (3.4) | 13 (3.3) |
| Endocrine therapy | ||||
| Yes | 617 (35.9) | 406 (42.5) | 228 (43.0) | 171 (42.8) |
| No | 877 (51.0) | 431 (45.1) | 241 (45.5) | 186 (46.5) |
| Recommended, unknown if administered | 141 (8.2) | 86 (9.0) | 39 (7.4) | 28 (7.0) |
| Unknown/missing | 84 (4.9) | 33 (3.5) | 22 (4.2) | 15 (3.8) |